Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Tomas J. Heyman is Director at Exelixis. OQRO lists 3 transactions filed with the SEC under this name, the latest on Sep 29, 2026, each linked to the official Form 4.
Director
Disclosures on record
3
Companies involved
2
As of the latest filing on , Tomas J. Heyman reported holding 50,649 shares of Exelixis (EXEL), worth about $3.4M at the last close of $67 (Nov 16, 2026). Holdings are also on file at Legend Biotech (LEGN); together they are worth about $4.26M.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Exelixis EXEL | 50,649 | 51K direct | $67 | $3.4M | May 27, 2026 |
| Legend Biotech LEGN | 53,720 | 54K direct | $16 | $859K | Sep 24, 2026 |
Is this Tomas J. Heyman’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Legend BiotechLEGN
Sep 24, 202621Kdisclosed Sep 29
DetailsOfficial recordExelixisEXEL
2 disclosures · May 2025 – May 2026 · 1 sold
May 27, 20268,367disclosed May 29
DetailsOfficial recordMay 21, 2025Sold~$201Kdisclosed May 22
DetailsOfficial recordTomas J. Heyman has no open-market purchase on record since 2025. Sales in 1 of the 2 years since 2025.
Tomas J. Heyman reported 0 open-market purchases and 1 sale since 2025; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2025 | — | $201K1×1 trade |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated May 27, 2026, Tomas J. Heyman reported holding 50,649 shares of Exelixis (EXEL). At the last close of $67 on Nov 16, 2026, that is about $3.4M. This is the stake disclosed in filings, not a net worth.
Tomas J. Heyman has no open-market purchase on record since 2025. Sales in 1 of the 2 years since 2025.
In SEC filings since 2025: no open-market purchase is on record; the latest open-market sale is from 2025.
Exelixis (EXEL), from 2025 to 2025: 0 purchases and 1 sale.
Tomas J. Heyman reported 0 open-market purchases and 1 sale here, 2025.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.